FDA Approves First Disease-Modifying Therapy for Children Newly Diagnosed With Stage 3 Type 1 Diabetes

The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab) for children and adolescents aged 8 to 17 who have been recently diagnosed with stage 3 type 1 diabetes.[1][2]

This regulatory decision marks a historic milestone in pediatric endocrinology. For the first time, a disease-modifying therapy is available for patients at the clinical onset of the disease, shifting the medical paradigm from merely replacing lost insulin to actively protecting the body's remaining insulin-producing cells.[2][3]

Type 1 diabetes is an autoimmune condition that develops in distinct, measurable stages. In stage 1 and stage 2, the immune system begins producing autoantibodies that mistakenly target the beta cells in the pancreas, but blood sugar levels remain largely manageable without the need for external insulin injections.[1][4]

By stage 3, the destruction of beta cells has progressed to the point where the body can no longer regulate blood glucose. This is the clinical diagnosis phase, characterized by sudden symptoms like excessive thirst, frequent urination, and severe fatigue, and it typically requires immediate, lifelong insulin therapy.[1][5]

Tzield, a CD3-directed monoclonal antibody, intervenes directly in this underlying autoimmune process. It works by binding to and modulating the specific T-cells that are responsible for the destruction of the pancreatic beta cells.[2][6]

By interrupting this self-destructive immune response, the intravenous therapy aims to preserve whatever endogenous insulin production the patient still has at the time of their stage 3 diagnosis, rather than simply treating the resulting high blood sugar.[4][6]

The FDA's accelerated approval is anchored in the results of the PROTECT phase 3 clinical trial, which was published in the New England Journal of Medicine. The randomized, double-blind, placebo-controlled study enrolled 328 children and adolescents who had been diagnosed with stage 3 type 1 diabetes within the previous six weeks.[1][4]

Participants in the trial received two 12-day courses of Tzield or a placebo, administered via intravenous infusion six months apart, alongside standard daily diabetes care and insulin management.[1][6]

The primary endpoint of the study was the preservation of beta-cell function, measured by testing the levels of C-peptide in the blood during a mixed-meal tolerance test. C-peptide is a reliable biological marker of how much natural insulin the body is still producing on its own.[1][4]

At the 78-week mark, the clinical data showed a statistically significant difference. Patients who received Tzield experienced a significantly smaller decline in C-peptide levels compared to those in the placebo group, demonstrating that the drug successfully slowed the loss of endogenous insulin production.[1][4]

However, the evidence also carries transparent clinical nuances. While the primary biological endpoint was met at the cellular level, researchers noted that secondary clinical endpoints—such as the total doses of insulin required, time spent in the target glucose range, and HbA1c levels—showed numerical trends favoring Tzield but did not reach statistical significance over the trial period.[4][7]

Despite this, patient advocacy groups emphasize that preserving beta-cell function is a profound victory. Breakthrough T1D, the research organization formerly known as JDRF, celebrated the approval, noting that maintaining natural insulin production can provide a crucial "honeymoon" period for newly diagnosed families.[3][7]

This preserved cellular function can make the disease less aggressive in its early clinical stages, reducing the immediate risk of severe complications like diabetic ketoacidosis and giving families precious time to adapt to the rigorous, round-the-clock demands of diabetes management.[3][5]

Tzield is not entirely new to the regulatory landscape. In November 2022, it became the first drug approved to delay the onset of stage 3 diabetes in patients aged 8 and older who were currently in stage 2.[2][5]

In April 2026, the FDA expanded that stage 2 indication to include children as young as one year old. The latest approval bridges the final gap, allowing clinicians to deploy the therapy even after clinical symptoms have appeared and insulin therapy has officially begun.[2][5]

Because this is an accelerated approval, the FDA requires Sanofi to conduct further confirmatory studies to verify the long-term clinical benefits of the drug. The ongoing BETA-PRESERVE phase 3 study is designed to substantiate these outcomes over a longer horizon.[1][2]

The FDA also highlighted important safety information for the newly approved indication. Tzield carries boxed warnings for leukopenia—a reduction in white blood cells—which can increase the risk of serious infections, requiring patients to be monitored closely during and after the infusion courses.[1][7]

Ultimately, the approval of Tzield for stage 3 type 1 diabetes represents a fundamental shift in endocrinology. It validates the decades-long effort to treat the root autoimmune cause of the disease, offering a new layer of hope for the 64,000 Americans diagnosed with type 1 diabetes each year.[3][7]